cefoselis

{{chembox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 462338588

| ImageFile=Cefoselis.png

| ImageSize=200px

| IUPACName=(6R,7R)-3-[[3-amino-2-(2-hydroxyethyl)pyrazol-1-ium-1-yl]methyl]-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

| OtherNames=Wincef

|Section1={{Chembox Identifiers

| CASNo_Ref = {{cascite|correct|??}}

| CASNo=122841-10-5

| PubChem= 5748845

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 2105940

| SMILES=CO/N=C(\C1=CSC(=N1)N)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=C(N4CCO)N)C(=O)[O-]

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 16736411

| InChI = 1/C19H22N8O6S2/c1-33-24-12(10-8-35-19(21)22-10)15(29)23-13-16(30)27-14(18(31)32)9(7-34-17(13)27)6-25-3-2-11(20)26(25)4-5-28/h2-3,8,13,17,20,28H,4-7H2,1H3,(H4,21,22,23,29,31,32)/b24-12-/t13-,17-/m1/s1

| InChIKey = BHXLLRXDAYEMPP-SBGRAJFYBO

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C19H22N8O6S2/c1-33-24-12(10-8-35-19(21)22-10)15(29)23-13-16(30)27-14(18(31)32)9(7-34-17(13)27)6-25-3-2-11(20)26(25)4-5-28/h2-3,8,13,17,20,28H,4-7H2,1H3,(H4,21,22,23,29,31,32)/b24-12-/t13-,17-/m1/s1

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = BHXLLRXDAYEMPP-SBGRAJFYSA-N

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 0B50MLU3H1

}}

|Section2={{Chembox Properties

| C=19 | H=22 | N=8 | O=6 | S=2

| Appearance=

| Density=

| MeltingPt=

| BoilingPt=

| Solubility=

}}

|Section3={{Chembox Hazards

| MainHazards=

| FlashPt=

| AutoignitionPt =

}}

}}

Cefoselis is a fourth generation cephalosporin. It is used extensively in Japan and China in the clinical treatment of various gram positive and gram negative infections. A 2014 study illustrated that Cefoselis is effective at treating respiratory and urinary tract infections.{{Cite web |date=2014-07-10 |title=Multicenter, double-blind, randomized clinical trial of parenterally administered Cefoselis versus Cefepime for the treatment of acute bacterial infections |url=https://www.europeanreview.org/article/7597 |access-date=2022-08-03 |website=European Review |language=en}}